MX2016000122A - Tratamiento de rosacea papulopustular con invermectina. - Google Patents

Tratamiento de rosacea papulopustular con invermectina.

Info

Publication number
MX2016000122A
MX2016000122A MX2016000122A MX2016000122A MX2016000122A MX 2016000122 A MX2016000122 A MX 2016000122A MX 2016000122 A MX2016000122 A MX 2016000122A MX 2016000122 A MX2016000122 A MX 2016000122A MX 2016000122 A MX2016000122 A MX 2016000122A
Authority
MX
Mexico
Prior art keywords
treatment
ivermectin
papulopustular rosacea
effective
methods
Prior art date
Application number
MX2016000122A
Other languages
English (en)
Inventor
Michel Poncet
Jean Jacovella
Alexandre Kaoukhov
Michael Graeber
Laurence Salin
Philippe Briantais
Jean-Paul Chappuis
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of MX2016000122A publication Critical patent/MX2016000122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/06—Holders for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos y composiciones para el tratamiento seguro y efectivo de rosácea papulopostular en un sujeto; los métodos implican aplicar de manera tópica a un área de piel afectada una composición tópica que contiene ivermectina y un portador farmacéuticamente aceptable; el tratamiento con ivermectina representa una terapia innovadora que es más fuerte y efectiva que los tratamientos convencionales.
MX2016000122A 2013-07-08 2014-07-08 Tratamiento de rosacea papulopustular con invermectina. MX2016000122A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843540P 2013-07-08 2013-07-08
US201361919208P 2013-12-20 2013-12-20
US201461927717P 2014-01-15 2014-01-15
US14/209,958 US9233118B2 (en) 2013-07-08 2014-03-13 Treatment of papulopustular rosacea with ivermectin
PCT/US2014/045739 WO2015006319A1 (en) 2013-07-08 2014-07-08 Treatment of papulopustular rosacea with ivermectin

Publications (1)

Publication Number Publication Date
MX2016000122A true MX2016000122A (es) 2016-06-15

Family

ID=52133217

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000121A MX2016000121A (es) 2013-07-08 2014-07-08 Tratamiento de lesiones inflamatorias de rosacea con invermectina.
MX2016000122A MX2016000122A (es) 2013-07-08 2014-07-08 Tratamiento de rosacea papulopustular con invermectina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016000121A MX2016000121A (es) 2013-07-08 2014-07-08 Tratamiento de lesiones inflamatorias de rosacea con invermectina.

Country Status (17)

Country Link
US (12) US9233117B2 (es)
EP (2) EP3019174A1 (es)
JP (7) JP6438466B2 (es)
KR (2) KR101864799B1 (es)
CN (4) CN105828825A (es)
AU (2) AU2014287408B2 (es)
BR (2) BR112016000335A8 (es)
CA (2) CA2916704C (es)
CL (2) CL2016000009A1 (es)
HK (2) HK1223841A1 (es)
IL (3) IL243315B (es)
MX (2) MX2016000121A (es)
NZ (2) NZ716033A (es)
RU (2) RU2633076C2 (es)
SG (2) SG11201510635PA (es)
WO (2) WO2015006319A1 (es)
ZA (1) ZA201600358B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102341441B1 (ko) 2013-11-29 2021-12-24 갈더마 홀딩 소시에떼 아노님 아토피성 피부염의 치료 및/또는 예방을 위한 아베르멕틴 패밀리 또는 밀베마이신 패밀리의 화합물
FR3032616B1 (fr) * 2015-02-12 2017-02-24 Galderma Sa Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
US11213539B2 (en) 2015-11-17 2022-01-04 Galderma Holding SA Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
AU2017305853B2 (en) * 2016-08-04 2023-04-13 Galderma Holding SA Compositions and the use thereof for treating or preventing rosacea
CN106397233A (zh) * 2016-08-26 2017-02-15 南通奥凯生物技术开发有限公司 一种医药级乙二胺四乙酸二钠的制备方法
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
RU2020122841A (ru) 2017-12-15 2022-01-18 Тарсус Фармасьютикалс, Инк. Изоксазолиновые паразитицидные составы и способы лечения блефарита
JP7129005B2 (ja) * 2018-09-28 2022-09-01 Toto株式会社 水洗大便器
EP3927349A1 (en) 2019-02-18 2021-12-29 Mary Kay, Inc. Topical skin compositions for treating rosacea and skin redness
CN111728959B (zh) * 2020-08-11 2023-02-03 黑龙江天龙药业有限公司 一种抑制油脂分泌且清螨虫的鼻膜贴及其制备方法
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations
JPWO2022269665A1 (es) * 2021-06-21 2022-12-29
KR102346125B1 (ko) 2021-10-15 2022-01-03 (주)나비바이오텍 이버멕틴 정성 검사용 래피드 키트

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA06863A (fr) 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6319945B1 (en) 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
DE10063946A1 (de) 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
US7064108B2 (en) 2002-02-08 2006-06-20 Merck & Co., Inc. Topical ivermectin composition
WO2003075656A2 (en) 2002-03-04 2003-09-18 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
FR2854074B1 (fr) * 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1620113B1 (en) 2003-04-24 2011-07-13 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
EP1600158A1 (en) 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886852B1 (fr) 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
WO2010072958A2 (fr) 2008-12-23 2010-07-01 Galderma S.A. Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
WO2010086726A1 (en) 2009-01-30 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for nail and skin treatment
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee

Also Published As

Publication number Publication date
MX2016000121A (es) 2016-07-14
US20180207188A1 (en) 2018-07-26
US20200000835A1 (en) 2020-01-02
US20160143935A1 (en) 2016-05-26
NZ716034A (en) 2017-01-27
IL243315B (en) 2022-02-01
CN111494399A (zh) 2020-08-07
JP2019073527A (ja) 2019-05-16
KR20160061311A (ko) 2016-05-31
SG11201510635PA (en) 2016-01-28
KR20160061310A (ko) 2016-05-31
JP2021059590A (ja) 2021-04-15
HK1223841A1 (zh) 2017-08-11
JP2017197562A (ja) 2017-11-02
EP3019174A1 (en) 2016-05-18
US20160175337A1 (en) 2016-06-23
US20180264021A1 (en) 2018-09-20
US20160184342A1 (en) 2016-06-30
JP2016526572A (ja) 2016-09-05
EP3019173A1 (en) 2016-05-18
AU2014287408A1 (en) 2016-02-11
CL2016000009A1 (es) 2016-08-19
JP2018184437A (ja) 2018-11-22
HK1223842A1 (zh) 2017-08-11
BR112016000350A8 (pt) 2020-01-07
CN111467301A (zh) 2020-07-31
US9233118B2 (en) 2016-01-12
SG11201510420UA (en) 2016-01-28
US20220347198A1 (en) 2022-11-03
NZ716033A (en) 2017-01-27
JP2023052490A (ja) 2023-04-11
IL243314B (en) 2022-02-01
WO2015006319A1 (en) 2015-01-15
BR112016000350A2 (pt) 2017-07-25
RU2016103753A (ru) 2017-08-11
US20150011490A1 (en) 2015-01-08
IL274058A (en) 2020-06-30
CN105792829A (zh) 2016-07-20
US20210177882A1 (en) 2021-06-17
KR101864799B1 (ko) 2018-06-05
BR112016000335A8 (pt) 2020-01-07
JP6438466B2 (ja) 2018-12-12
RU2633481C2 (ru) 2017-10-12
CA2916704C (en) 2018-11-20
JP6653734B2 (ja) 2020-02-26
BR112016000335A2 (pt) 2017-07-25
US20180177813A1 (en) 2018-06-28
US20150011491A1 (en) 2015-01-08
CA2916668A1 (en) 2015-01-15
CL2016000008A1 (es) 2016-08-05
IL274058B (en) 2022-02-01
US9233117B2 (en) 2016-01-12
RU2016103715A (ru) 2017-08-11
AU2014287408B2 (en) 2017-05-04
US9089587B2 (en) 2015-07-28
CN105828825A (zh) 2016-08-03
AU2014287422A1 (en) 2016-02-11
RU2633076C2 (ru) 2017-10-11
AU2014287422B2 (en) 2017-04-13
US10206939B2 (en) 2019-02-19
KR101863085B1 (ko) 2018-06-01
JP2016523968A (ja) 2016-08-12
IL243314A0 (en) 2016-02-29
IL243315A0 (en) 2016-02-29
CA2916704A1 (en) 2015-01-15
ZA201600358B (en) 2019-11-27
US20150011489A1 (en) 2015-01-08
WO2015006305A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
NZ716033A (en) Treatment of papulopustular rosacea with ivermectin
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
NZ749218A (en) Androgen receptor modulator and uses thereof
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
WO2015009726A3 (en) Medical uses of cd38 agonists
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
MX366502B (es) Composiciones y métodos para tratar heridas superficiales.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2019013862A (es) Terapia de combinacion.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
WO2014153385A3 (en) Methods of treating metabolic disorders
GB2525517A (en) Topical preparation for pain relief
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
NZ713046A (en) Therapeutic compositions for the treatment and prevention of gastrointestinal cancer